Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Accured Expenses (2020 - 2025)

Bioventus (BVS) has disclosed Change in Accured Expenses for 6 consecutive years, with -$4.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 126.74% year-over-year to -$4.4 million, compared with a TTM value of -$19.8 million through Dec 2025, down 211.03%, and an annual FY2025 reading of -$19.8 million, down 211.03% over the prior year.
  • Change in Accured Expenses was -$4.4 million for Q4 2025 at Bioventus, down from $7.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $29.9 million in Q2 2024 and bottomed at -$39.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $393450.0, with a median of $5.1 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses skyrocketed 862.23% in 2021, then tumbled 911.94% in 2022.
  • Year by year, Change in Accured Expenses stood at $11.0 million in 2021, then skyrocketed by 30.53% to $14.3 million in 2022, then plummeted by 59.53% to $5.8 million in 2023, then soared by 186.98% to $16.6 million in 2024, then tumbled by 126.74% to -$4.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for BVS at -$4.4 million in Q4 2025, $7.3 million in Q3 2025, and $16.4 million in Q2 2025.